Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04242849
Recruitment Status : Completed
First Posted : January 27, 2020
Last Update Posted : January 27, 2020
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
Josep Carreras Leukaemia Research Institute

Brief Summary:

In a spanish series of AML patients it is intended to perform, at the moment of diagnosis, pyrosequencing of IDH1 and IDH2 genes. Taking into account the incidence of AML in the area, it is planed to study 100 patients per year.

Among the cases with IDH1/2 mutations, targeted deep sequencing (TDS) of a panel covering coding regions of 40 myeloid related genes will be applied. With TDS, pyrosequencing results will be validated at the same time that prognosis value of co-mutated genes could be studied. Furthermore, with TDS, molecular architecture of IDH1 and IDH2 mutated cases might be better understood.


Condition or disease
Acute Myeloid Leukemia

Layout table for study information
Study Type : Observational
Actual Enrollment : 354 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up
Actual Study Start Date : May 23, 2016
Actual Primary Completion Date : December 27, 2019
Actual Study Completion Date : January 16, 2020


Group/Cohort
IDH1/2 mutated patients
Patients harboring mutations in IDH1 or IDH2 genes
Patients without IDH1/2 mutations
Patients that don´t present any mutation in IDH1/2 genes



Primary Outcome Measures :
  1. Presence of IDH1/2 mutation [ Time Frame: 1 day ]
    Detection of mutations in IDH1 and IDH2 genes


Secondary Outcome Measures :
  1. Detection of co-mutations [ Time Frame: 1 day ]
    Screening of aditional mutations in those cases with IDH1/2 mutation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sampling Method:   Non-Probability Sample
Study Population
Patients >18 years old with de novo acute myeloid leukemia (AML).
Criteria

Inclusion Criteria:

  • Patients >18 years old with de novo acute myeloid leukemia will be included. All patients will be treated according to clinical routine.

Exclusion Criteria:

  • Patients not following the above criteria.
Layout table for additonal information
Responsible Party: Josep Carreras Leukaemia Research Institute
ClinicalTrials.gov Identifier: NCT04242849    
Other Study ID Numbers: N/A-NI-AML-PI-007344
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No